Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan-based Conditioning for Fanconi Anemia
NCT00987480Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2009
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in Fanconi anemia (FA), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Successful Neutrophil Engraftment at 2 years, The Incidence of Early Transplant Related Mortality at 2 years and 2 more. Started Sep 2009; status: completed.
02
Drugs
busulfan
03
Conditions
Fanconi anemia (FA)
Beyond the preview
Go deeper on NCT00987480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00987480.